Back to Search
Start Over
The use of same in chemotherapy-induced liver injury
- Publication Year :
- 2018
- Publisher :
- Elsevier Ireland Ltd, 2018.
-
Abstract
- Drug-induced liver injury (DILI) remains the most common cause of acute liver failure in the Western world. Chemotherapy is one of the major class of drugs most frequently associated with idiosyncratic DILI. For this reason, patients who receive chemotherapy require careful assessment of liver function prior to treatment to determine which drugs may not be appropriate and which drug doses should be modified. S-adenosylmethionine (SAMe) is an endogenous agent derived from methionine. Its supplementation is effective in the treatment of liver disease, in particular intrahepatic cholestasis (IHC). The target of this review is to analyze the mechanisms of hepatotoxicity of the principal anticancer agents and the role of SAMe in the prevention of this complication.
- Subjects :
- medicine.medical_specialty
Drug-Related Side Effects and Adverse Reactions
Drug-induced liver injury
Settore MED/06 - Oncologia Medica
medicine.medical_treatment
Antineoplastic Agents
Gastroenterology
03 medical and health sciences
Liver disease
0302 clinical medicine
Cholestasis
Chemotherapy induced
Internal medicine
Neoplasms
medicine
Animals
Humans
Chemotherapy
Liver injury
S-adenosylmethionine
business.industry
Hepatotoxicity
Hematology
medicine.disease
Oncology
Cholestasi
030220 oncology & carcinogenesis
Immunohistochemistry
030211 gastroenterology & hepatology
Liver function
Chemical and Drug Induced Liver Injury
Complication
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....5c0e7bfeb9c6461377a2b849cae77749